Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-011
2022-501697-19-00Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised trial of nemtabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Merck & Co. Primary endpoints: Objective Response Rate (ORR) and Progression-Free Survival (PFS). Planned start Jan 2024; status: withdrawn.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2022-501697-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501697-19-00.